芬戈莫德联合倍他司汀对缺血性脑卒中患者血流动力学指标及血清相关细胞因子水平的影响  

Effects of Fingolimod combined with Betahistine on hemodynamic indexes and serum levels of related cytokines in patients with ischemic stroke

作　　者：刘平 陈德鹏[1] 吕彤 陈东阳 Liu Ping;Chen De-peng;Lv Tong;Chen Dong-yang(Department of Neurology,The First Affiliated Hospital of Nanyang Medical College,Nanyang 473007,Henan,China)

机构地区：[1]南阳医学高等专科学校第一附属医院神经内科重症监护室,河南南阳473007

出　　处：《四川生理科学杂志》2025年第1期67-70,共4页

摘　　要：目的:观察芬戈莫德联合倍他司汀治疗缺血性脑卒中(Ischemic stroke,IS)患者的疗效及其应用价值。方法:选取2021年10月至2023年10月本院90例IS患者分为对照组、观察组,各45例。对照组口服倍他司汀(10 mg·次^(-1),2次·d^(-1)),观察组口服芬戈莫德(0.5 mg·次^(-1),2次·d^(-1))+倍他司汀,连续治疗2 m。比较两组临床疗效。治疗前、治疗2 m后采用全自动血流变仪检测血浆黏度、红细胞压积、血小板黏附率;采用酶联免疫吸附(Enzyme linked immunosorbent assay,ELISA)法检测白细胞介素-1β(Interleukin-1β,IL-1β)、白细胞介素-2(Interleukin-2,IL-2)、肿瘤坏死因子-α(Tumor necrosis factor-alpha,TNF-α)水平;并采用放射免疫法检测内皮素-1(Endothelin-1,ET-1)、血栓素B2(Thromboxane B2,TXB2)水平;采用ELISA法检测血管内皮生长因子(Vascular endothelial growth factor,VEGF)水平。同时,比较两组不良反应发生率。结果:观察组总有效率高于对照组(P<0.05);与对照组比较,观察组治疗后血浆黏度y、红细胞压积、血小板黏附率降低(P<0.05);与对照组比较,观察组治疗后血清IL-1β、IL-2、TNF-α水平降低(P<0.05);与对照组比较,观察组治疗后血清ET-1、TXB2水平降低,VEGF水平升高(P<0.05);两组治疗期间均无明显不良反应。结论:芬戈莫德联合倍他司汀治疗IS的疗效确切,可改善血流动力学,抑制炎性反应,减轻血管内皮损伤,且具有一定安全性。Objective:To observe the efficacy and application value of fingolimod combined with betahistine in the treatment of ischemic stroke(IS)patients.Methods:A total of 90 patients with IS in our hospital from October 2021 to October 2023 were selected and divided into a control group and an observation group,with 45 patients in each group.The control group was treated with betahistine(10 mg Bid)orally,while the observation group was treated with fingolimod(0.5 mg Bid)plus betahistine orally for 2 months.The clinical efficacy of the two groups was compared.Before and after treatment,the plasma viscosity,hematocrit,and platelet adhesion rate were measured using a fully automated hemorheology analyzer.The levels of interleukin-1β(IL-1β),interleukin-2(IL-2),and tumor necrosis factor-alpha(TNF-α)were detected using enzyme-linked immunosorbent assay(ELISA).The levels of endothelin-1(ET-1)and thromboxane B2(TXB2)were detected using radioimmunoassay.The level of vascular endothelial growth factor(VEGF)was detected using ELISA.At the same time,the incidence of adverse reactions in both groups was compared.Results:The total effective rate in the observation group was higher than that in the control group(P<0.05).Compared with the control group,the plasma viscosity,hematocrit,and platelet adhesion rate decreased in the observation group after treatment(P<0.05).Compared with the control group,the levels of serum IL-1β,IL-2,and TNF-αdecreased in the observation group after treatment(P<0.05).Compared with the control group,the levels of serum ET-1 and TXB2 decreased and the level of VEGF increased in the observation group after treatment(P<0.05).There were no significant adverse reactions during treatment in both groups.Conclusion:Fingolimod combined with betahistine has a definite therapeutic effect in the treatment of IS,which can improve hemodynamics,inhibit inflammatory reactions,alleviate vascular endothelial injury,and have certain safety.

关 键 词：缺血性脑卒中 芬戈莫德 倍他司汀 疗效 血流动力学 

分 类 号：R743.3[医药卫生—神经病学与精神病学]